drugset / Trial / NCT07434843
PH 2 Pemigatinib in SDH-deficient GIST
Phase 2
Recruiting
24 enrolled
Dana-Farber Cancer Institute
Gateway for Cancer Research · collabIncyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)
Timeline
- Start
- 2026-05-19
- Primary completion
- 2028-10-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | — | Oral |